Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine

European Journal of Pharmacology

Volumn 596, Issue 1-3, 2008, Pages 89-97

  Li, Zhu ^a   Snigdha, Shikha ^a   Roseman, Alex S ^a   Dai, Jin ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Microdialysis; Muscarinic; Risperidone; Sabcomeline; Schizophrenia; Xanomeline

Indexed keywords

AC 260584; ACETYLCHOLINE; CLOZAPINE; DOPAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; NORCLOZAPINE; RISPERIDONE; SABCOMELINE; TELENZEPINE; UNCLASSIFIED DRUG; XANOMELINE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ARTICLE; COGNITION; DOPAMINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; LOW DRUG DOSE; MALE; METABOLITE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOXAZINES; BRAIN; CLOZAPINE; DOPAMINE; DRUG SYNERGISM; IMINES; MALE; NUCLEUS ACCUMBENS; PIRENZEPINE; PREFRONTAL CORTEX; PYRIDINES; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; RISPERIDONE; THIADIAZOLES;

EID: 53049096358     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.08.009     Document Type: Article

References (68)

1. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., and Silva A.J. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 6 (2003) 51-58
2. Bartolomeo A.C., Morris H., Buccafusco J.J., Kille N., Rosenzweig-Lipson S., Husbands M.G., Sabb A.L., Abou-Gharbia M., Moyer J.A., and Boast C.A. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J. Pharmacol. Exp. Ther. 292 (2000) 584-596
3. 2 through a correlation of in vivo microdialysis and in vitro receptor binding data. J. Pharmacol. Exp. Ther. 273 (1995) 273-279
4. Bodick N.C., Offen W.W., Shannon H.E., Satterwhite J., Lucas R., van Lier R., and Paul S.M. The selective muscarinic receptor agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 11 Suppl 4 (1997) S16-S22
5. Bonner T.I. New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. Suppl. (1989) 11-15
6. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., Nash N.R., Olsson R., Davis R.E., Hacksell U., Weiner D.M., and Brann M.R. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
7. Bymaster F.P., Heath I., Hendrix J.C., and Shannon H.E. Comparative behavioral and neurochemical activities of cholinergic receptor antagonists in rats. J. Pharmacol. Exp. Ther. 267 (1993) 16-24
8. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
9. Bymaster F.P., Felder C., Ahmed S., and McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Current Drug Targets-CNS & Neurological Disorders 1 (2002) 147-164
10. Chung Y.C., Li Z., Dai J., Meltzer H.Y., and Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 1023 (2004) 54-63
11. Davis K.L., Hollister L.E., Berger P.A., and Barchas J.D. Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation. Psychopharmacol. Commun. 1 (1975) 533-543
12. Davies M.A., Compton-Toth B.A., Hufeisen S.J., Meltzer H.Y., and Roth B.L. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?. Psychopharmacology (Berl.) 178 (2005) 451-460
13. De Boer P., Damsma G., Fibiger H.C., Timmerman W., De Vries J.B., and Westerink B.H.C. Dopaminergic-cholinergic interactions in the striatum: the critical significance of calcium concentrations in brain microdialysis. Naunyn-Schmiedeberg's Arch Pharmacol. 342 (1990) 528-534
14. Dean B., Bymaster F.P., and Scarr E. Muscarinic receptors in schizophrenia. Curr. Mol. Med. 3 (2003) 419-426
15. Fink-Jensen A., Kristensen P., Shannon H.E., Calligaro D.O., Delapp N.W., Whitesitt C., Ward J.S., Thomsen C., Rasmusseen T., Sheardown M.J., Jeppesen L., Sauerberg P., and Bymaster F.P. Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats. Neuroreport 9 (1998) 3481-3486
16. Flynn D.D., Ferrari-DiLeo G., Mash D.C., and Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 64 (1995) 1888-1891
17. 1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15312-15317
18. Grayson B., Idris N.F., and Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 184 (2007) 31-38
19. Gronier B., and Rasmussen K. Pertussis toxin treatment differentially affects cholinergic and dopaminergic receptor stimulation of midbrain dopaminergic neurons. Neuropharmacology 38 (1999) 1903-1912
20. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 (2002) 325-339
21. 1/4 agonism in schizophrenia. Program No. 950.13. 2004 Abstract Viewer/Itinerary Planner (2004), Society for Neuroscience, Washington, DC Online
22. Jones C.K., and Shannon H.E. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J. Pharmacol. Exp. Ther. 294 (2000) 1017-1023
23. Jones C.K., Eberle E.L., Shaw D.B., McKinzie D.L., and Shannon H.E. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J. Pharmacol. Exp. Ther. 312 (2005) 1055-1063
24. King D.J. The effect of neuroleptics on cognitive and psychomotor function. Br. J. Psychiatry 157 (1990) 799-811
25. 4, receptor supports its role as autoreceptors in the rat hippocampus. Mol. Brain Res. 67 (1999) 98-106
26. Kuoppamäki M., Syvälahti E., and Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur. J. Pharmacol. 245 (1993) 179-182
27. Kuroki T., Meltzer H.Y., and Icikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288 (1999) 774-781
28. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., and Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11 (1991) 3218-3226
29. Levin E.D., McGurk S.R., Rose J.E., and Butcher L.L. Cholinergic-dopaminergic interactions in cognitive performance. Behav. Neural. Biol. 54 (1990) 271-299
30. Li Z., Ichikawa J., and Meltzer H.Y. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 167 (2003) 315-323
31. 1 muscarinic receptors. Neuropsychopharmacology 30 (2005) 1986-1995
32. 1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur. J. Pharmacol. 572 (2007) 129-137
33. 1 receptors. J. Pharmacol. Exp. Ther. 283 (1997) 1059-1068
34. Marshall D.L., and Wurtman R.J. Effect of choline on basal and stimulated acetylcholine release: an in vivo microdialysis study using a low neostigmine concentration. Brain Res. 269 (1993) 353-362
35. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognition in schizophrenia. Schizophr. Bull. 25 (1999) 233-256
36. Miller A.D., and Blaha C.D. Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat. Eur. J. Neurosci. 21 (2005) 1837-1846
37. 1 muscarinic acetylcholine receptor. J. Neurosci. 21 (2001) 5239-5250
38. Moghaddam B., and Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54 (1990) 1755-1760
39. Murakami Y., Matsumoto K., Ohta H., and Watanabe H. Effects of oxotremorine and pilocarpine on striatal acetylcholine release as studied by brain dialysis in anesthetized rats. Gen. Pharmacol. 27 (1996) 833-836
40. 1 muscarinic receptor agonist on the central cholinergic system, evaluated by brain microdialysis. Neurosci. Lett. 114 (1990) 95-100
41. 1 agonist, AF102B. Eur. J. Pharmacol. 155 (1988) 77-84
42. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, New York
43. Pramanik A., and Ögren S.V. Galanin stimulates striatal acetylcholine release via a mechanism unrelated to cholinergic receptor stimulation. Regul. Pept. 45 (1993) 353-362
44. Quirion R., Richard J., and Wilson A. Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats. Synapse 17 (1994) 92-100
45. Raedler T.J., Bymaster F.P., Tandon R., Copolov D., and Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 12 (2007) 232-246
46. Ringdahl B., Roch M., and Jenden D.J. Regional differences in receptor reserve for analogs of oxotremorine in vivo: implications for development of selective muscarinic agonists. J. Pharmacol. Exp. Ther. 242 (1987) 464-471
47. 1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats. Neurosci. Lett. 230 (1997) 93-96
48. Rossi A., Humancini F., and Stratta P. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 95 (1997) 40-43
49. Sato M., Ago Y., Koda K., Nakamura S., Kawasaki T., Baba A., and Matsuda T. Role of postsynaptic serotoninia receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur. J. Pharma. 559 (2007) 155-160
50. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124 (1996) 57-73
51. 1 receptors. J. Pharmacol. Exp. Ther. 269 (1994) 271-281
52. Shannon H.E., Rasmussen K., Bymaster F.P., Hart J.C., Peters S.C., Swedberg M.D., Jeppesen L., Sheardown M.J., Sauerberg P., and Fink-Jensen A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr. Res. 42 (2000) 249-259
53. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 (2002) 583-594
54. 1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol. Pharmacol. 70 (2006) 1974-1983
55. Spohn H.E., and Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98 (1989) 367-380
56. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., Kennett G.A., Lightowler S., Sheardown M.J., Syed R., Upton R.L., Wadsworth G., Weiss S.M., and Wyatt A. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J. Pharmacol. Exp. Ther. 299 (2001) 782-792
57. 2 antagonists on in vivo hippocampal acetylcholine levels. Brain Res. Bull. 41 (1996) 221-226
58. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., and Conn P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13674-13679
59. Suzuki T., Hirooka K., Kanda K., Uesaka H., Hirooka H., and Furusawa K. Characterization of the neurochemical effects of N-[2-(1-azabicyclo[3,3,0]octan-5-yl)ethyl]2-nitroaniline fumarate (SK-946) as a cognition activator. Biol. Pharm. Bull. 21 (1998) 704-709
60. 2 receptors. Brain Res. 726 (1996) 207-212
61. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 63 (2001) 241-320
62. 1 receptors modulate anxiety-like behaviour and spontaneous working memory in mice. Psychopharmacology (Berl). 1 (2001) 58-68
63. 5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J. Neurochem. 63 (1994) 815-821
64. 1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl.) 177 (2004) 207-216
65. 1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons. J. Neurosci. 20 (2000) 783-790
66. Westerink B.H.C., De Boer P., and Damsma G. Dopamineacetylcholine interaction in the striatum studied by microdialysis in the awake rat: some methodological aspects. J. Neurosci. Met. 34 (1990) 117-124
67. Wood M.D., Murkitt K.L., Ho M., Watson J.M., Brown F., Hunter A.J., and Middlemiss D.N. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br. J. Pharmacol. 126 (1999) 1620-1624
68. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol 8 (2005) 457-472